JPWO2021060341A1 - - Google Patents
Info
- Publication number
- JPWO2021060341A1 JPWO2021060341A1 JP2021548966A JP2021548966A JPWO2021060341A1 JP WO2021060341 A1 JPWO2021060341 A1 JP WO2021060341A1 JP 2021548966 A JP2021548966 A JP 2021548966A JP 2021548966 A JP2021548966 A JP 2021548966A JP WO2021060341 A1 JPWO2021060341 A1 JP WO2021060341A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019175495 | 2019-09-26 | ||
| PCT/JP2020/035945 WO2021060341A1 (ja) | 2019-09-26 | 2020-09-24 | Ｄｎｍｔ阻害剤の用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPWO2021060341A1 true JPWO2021060341A1 (https=) | 2021-04-01 |
Family
ID=75166998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021548966A Pending JPWO2021060341A1 (https=) | 2019-09-26 | 2020-09-24 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US12472196B2 (https=) |
| JP (1) | JPWO2021060341A1 (https=) |
| CN (1) | CN114423438A (https=) |
| WO (1) | WO2021060341A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116940365A (zh) * | 2021-02-23 | 2023-10-24 | 大原药品工业株式会社 | 慢性髓性白血病干细胞抑制剂 |
| WO2025142803A1 (ja) * | 2023-12-25 | 2025-07-03 | 大原薬品工業株式会社 | Ｄｎｍｔ阻害剤の経口投与用の医薬組成物 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030147813A1 (en) * | 2002-02-07 | 2003-08-07 | John Lyons | Method for treating chronic myelogenous leukemia |
| JP2017531639A (ja) * | 2014-10-08 | 2017-10-26 | エピジェネティクス・ファーマ・エルエルシー | シリル化ピリミジンプロドラッグ及びその使用方法 |
| WO2017183217A1 (ja) * | 2016-04-21 | 2017-10-26 | 大原薬品工業株式会社 | ５－アザシチジン類の糖部シリルエーテル誘導体 |
| WO2019160127A1 (ja) * | 2018-02-19 | 2019-08-22 | 大原薬品工業株式会社 | Ｄｎｍｔ阻害剤の用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7700567B2 (en) * | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| CA2975988C (en) * | 2015-02-04 | 2020-07-21 | Medpacto Inc. | Combination of a tgf-b inhibitor and a bcr-abl tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia |
-
2020
- 2020-09-24 JP JP2021548966A patent/JPWO2021060341A1/ja active Pending
- 2020-09-24 CN CN202080064218.7A patent/CN114423438A/zh active Pending
- 2020-09-24 US US17/641,083 patent/US12472196B2/en active Active
- 2020-09-24 WO PCT/JP2020/035945 patent/WO2021060341A1/ja not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030147813A1 (en) * | 2002-02-07 | 2003-08-07 | John Lyons | Method for treating chronic myelogenous leukemia |
| JP2017531639A (ja) * | 2014-10-08 | 2017-10-26 | エピジェネティクス・ファーマ・エルエルシー | シリル化ピリミジンプロドラッグ及びその使用方法 |
| WO2017183217A1 (ja) * | 2016-04-21 | 2017-10-26 | 大原薬品工業株式会社 | ５－アザシチジン類の糖部シリルエーテル誘導体 |
| WO2019160127A1 (ja) * | 2018-02-19 | 2019-08-22 | 大原薬品工業株式会社 | Ｄｎｍｔ阻害剤の用途 |
Non-Patent Citations (3)
| Title |
|---|
| HATTORI NAOKO ET AL.: "Novel prodrugs of decitabine with greater metabolic stability and less toxicity", CLINICAL EPIGENETICS, vol. 11, no. 111, JPN6020044824, 1 August 2019 (2019-08-01), pages 1 - 12, ISSN: 0005111231 * |
| ISSA JEAN-PIERRE J. ET AL.: "Decitabine in Chronic Leukemias", SEMINARS IN HEMATOLOGY, vol. Vol.42, No.3, Suppl.2, JPN6020044825, 2005, pages 43 - 49, ISSN: 0005111232 * |
| OKI YASUHIRO ET AL.: "Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with acceler", CANCER, vol. 109, no. 5, JPN6020044826, 2007, pages 899 - 906, XP002573031, ISSN: 0005111233, DOI: 10.1002/cncr.22470 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114423438A (zh) | 2022-04-29 |
| US20220347197A1 (en) | 2022-11-03 |
| WO2021060341A1 (ja) | 2021-04-01 |
| US12472196B2 (en) | 2025-11-18 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220126 |
|
| AA64 | Notification of invalidation of claim of internal priority (with term) |
Free format text: JAPANESE INTERMEDIATE CODE: A241764 Effective date: 20220412 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220419 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220427 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221223 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230217 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230420 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230721 |